Table 1.

Clinical trials included in this meta-analysis

	Country	Patients (n) *	Triptan	Dose	Migraine subtype	Treatment duration	Day of treatment onset	Consecutive PMP
Silberstein (2004)[33]	USA	506	frovatriptan	2.5 mg QD or BID	MAM**	6	−2	1
Brandes (2009)[7]	International	410	frovatriptan	2.5 mg QD or BID	MM	6	−2	3
Newman (2001)[34]	USA	206	naratriptan	1 mg or 2.5mg BID	MAM**	5	−2	4
Mannix (s1) (2007)[35]	USA	287	naratriptan	1 mg BID	MRM**	6	−3	4
Mannix (s2) (2007)[35]	International	346	naratriptan	1 mg BID	MRM**	6	−3	4
Tuchman (2008)[36]	USA	244	zolmitriptan	2.5 mg BID or TID	MM**	7	−2	3

* intention-to-treat population.

** used Headache Society (IHS) 1988 criteria.